ABSTRACT
INTRODUCTION
In biomedical studies, a considerable interest is laid upon developing statistical techniques for analyzing survival data which utilize information available on concomitant variables. In classical analysis of survival data, several models [1] [2] [3] [4] [5] [6] [7] are used for such situations. The usual proportional hazards (PH) regression model proposed by Cox [8] has been extensively discussed in the literature. Byar et al. [9] and Greenberg et al. [10] presented analysis of survival data assuming linear hazard model in classical set-up.
Bhattacharya et al. [11] discussed for the first time the problem on estimation of survival probabilities adjusting the effect of a single concomitant variable in the Bayesian framework. The present paper presents the Bayesian and hierarchical Bayesian analysis of response-time data in more general situations of more 
representing the death density function (DDF) corresponding to the survival time Y is assumed. We also assume that the hazard λ for a patient under clinical investigation is linearly related to measurements on 'p' concomitant variables x 1 , x 2 , . . . , λ λ t; x β β x β x 0 β ,β ,...,β
where β 0 , β 1 , . . . . , β p are (p + 1) unknown parameters and x 0 = 1 is a dummy variable which is set equal to 1 for all individuals for notational symmetry. In (2) β 0 can be interpreted as the underlying hazard rate or the intercept. Of course, it is necessary that the right hand side of (2) be positive. The above hazard model can also be written as [12] gave specific applications of the Cox model to the analysis of dose-response experiments. The detailed account of dose-response models is available in an expository paper by Kalbfleisch et al. [13] .
Bayesian and hierarchical Bayesian estimation of the parameters β 0 , β 1 , . . . , β p , the hazard rate, and the survival function are presented here under the assumptions of the squared error loss function (SELF) and suitable joint prior density of (β 0 , β 1 , . . . , β p ). A numerical illustration based on the model (2) is presented for survival data set on advanced lung cancer patients.
TOOLS AND TECHNIQUES

Model Parameters
Under the model assumptions (1) and (2), the hazard rate (HR) and the survival function (SF) are respectively given by
The SF (5) gives the probability of survival of an individual with a given vector x  of concomitant variables, up to time t measured from the chosen origin, which may be the start of the clinical study or the point at diagnosis.
Data Set
It is assumed that 'n' individuals enter the clinical study at different points of time and the clinical study lasts a predetermined follow-up period t = T 0 . Let 'd' be the number of individuals responding prior to the follow-up period T 0 , then the rest of individuals, say s = (n -d) consist of those who are lost to follow-up at different time points during the study and those who did not respond till the end of the clinical study. This type of censoring is also known as "progressive censoring" in the literature. It is also assumed that measurements on (p + 1) concomitant variables for all the patients are also available. For this situation the sample data will consist of the observation vectors (t j , x j0 , x j1 , . . . , x jp ), j = 1, 2, . . . , d and (t 
Likelihood Function
For the hazard model (2) and the Type III censored sample data set described earlier LF works out as
The product term in (6) can be written as a sum as 
Throughout this paper, g and g* will be used as the generic notations for the prior and the posterior densities respectively and the loss structure will be characterized by the usual squared error loss function (SELF). We shall also use the generic notation K for the normalization constant.
BAYESIAN ESTIMATION OF THE MODEL PARAMETERS
Here it is assumed that prior densities of β 0 , β 1 , . . . , β p mentioned earlier are a priori independent and that β r , r = 0, 1, 2, . . . , p, follows the gamma prior density with known scale and shape hyperparameters b r and a r respectively. For this situation, the joint prior density of (β 0 , β 1 , . . . , β p ) is given by
The Bayesian results for the non-informative prior quasi-density (NPQD) specified by
are also obtained. The role of NPQD in Bayesian analysis is elucidated in a basic paper of Bhattacharya [14] .
The raison d of their use are available in Raiffa and Schlaifer [15] .
On the basis of sample data set described earlier, the Bayesian posterior density of ( 0 ,  1 , . . . ,  p <∞) is obtained by combining the LF (10) and joint prior density (11) with the help of the Bayes theorem. This works out to be   
From (13), the marginal posterior density of  r (r = 0, 1, . . , p) is given by
Under the assumption of the SELF, the Bayes estimator of  r (r = 0, 1, 2, . . ., p) and its posterior variance respectively are obtainable from the following expressions
The Bayes estimator of the SF is given by the expression:
Evaluating the above multiple integral we obtain 
Similarly, the posterior variance of Ŝ (t; x) is obtained as 
where r β  (r = 0, 1, 2, . . . , p) is to be substituted from (16) . The Bayesian results for the NPQD (12) can be obtained from those corresponding to the prior density (11) given above, by replacing b r = 0, and a r = 1, r = 0, 1, 2, . . . p.
HIERARCHICAL BAYESIAN ESTIMATION OF THE MODEL PARAMETERS
In hierachical Bayes approach [16] [17] [18] [19] [20] 
From (22) and (23) 
Assuming a priori independence, the joint prior density of ( 0 ,  1 , . . . ,  p ) in this case comes out to be
On the basis of sample data set described earlier obtained by combining the LF (10) joint prior density (25) with the help of the Bayes theorem. This works out to be
where K can be computed by using the result (A.2) of the appendix as 
where comitant variables are presented in Table 2 . Figures 1 to  4 provide the plots of estimates of the survival function of standard and test therapies for different tumor cell types.
From the comparison of estimates for the two therapies, for given arbitrary concomitant vector x  for squamous and adeno tumor cell types, the test therapy prolong the survival of patients. The test therapy comes out to be the most effective for adeno tumor cell type for this particular case.
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